Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Medtronic PLC (NYSE:MDT)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Medtronic PLC (NYSE:MDT). In a filing disclosed on June 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Medtronic stock on May 15th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.

Medtronic Stock Down 2.1%

MDT stock opened at $80.27 on Thursday. The firm’s fifty day simple moving average is $81.10 and its 200-day simple moving average is $91.60. The company has a market capitalization of $103.06 billion, a P/E ratio of 21.52, a price-to-earnings-growth ratio of 2.00 and a beta of 0.58. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. Medtronic PLC has a 12 month low of $73.31 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. The business had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.61%. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, equities research analysts forecast that Medtronic PLC will post 5.94 earnings per share for the current year.

Medtronic Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be issued a $0.72 dividend. This is an increase from Medtronic’s previous quarterly dividend of $0.71. The ex-dividend date of this dividend is Friday, June 26th. This represents a $2.88 annualized dividend and a dividend yield of 3.6%. Medtronic’s payout ratio is currently 76.14%.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the company’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the transaction, the executive vice president directly owned 37,227 shares in the company, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.26% of the company’s stock.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic received FDA clearance for an updated Nellcor pulse oximetry system, which should help its monitoring portfolio and improve performance across diverse patient groups. Medtronic gets FDA nod for updated pulse oximetry system
• Positive Sentiment: The company earned CE mark approval for its Stealth AXiS robotic platform in ENT surgery, expanding its reach in Europe and supporting future procedure volume. Medtronic earns CE mark for Stealth AXiS robot platform in ENT surgery
• Positive Sentiment: Investor sentiment toward healthcare has improved as money rotates out of tech and into defensive sectors, which can help MDT relative to the broader market. As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play
• Positive Sentiment: Recent commentary has highlighted Medtronic as attractively valued at about 14x forward earnings with a 3.5% dividend yield and steady fiscal 2027 guidance. Is Medtronic Stock a Buy at 14x Forward Earnings?
• Neutral Sentiment: Analysts remain broadly constructive, but some recent price-target cuts suggest expectations have been reset after the latest earnings update.
• Neutral Sentiment: MarketWatch noted Medtronic underperformed some peers despite gains, indicating investors are still favoring stronger near-term names in the sector. Medtronic PLC stock underperforms Tuesday when compared to competitors despite daily gains
• Negative Sentiment: EVP Harry Skip Kiil sold 4,189 shares, a transaction that can modestly weigh on sentiment even if it may be routine. Harry Skip Kiil insider transaction
• Negative Sentiment: Investors also appear focused on margin pressure risks from tariffs and mix shifts, which could limit upside despite steady growth. Is Medtronic Stock a Buy at 14x Forward Earnings?

Wall Street Analyst Weigh In

MDT has been the topic of several recent research reports. Argus dropped their price objective on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a report on Monday, April 6th. Weiss Ratings cut shares of Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, May 21st. Mizuho decreased their target price on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating for the company in a research note on Wednesday, June 3rd. Evercore set a $106.00 target price on shares of Medtronic and gave the company an “outperform” rating in a research note on Thursday, April 9th. Finally, Sanford C. Bernstein decreased their target price on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating for the company in a research note on Thursday, June 4th. Seventeen research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $99.00.

Hedge Funds Weigh In On Medtronic

Several large investors have recently made changes to their positions in the company. Lodestone Wealth Management LLC acquired a new position in Medtronic during the fourth quarter worth $27,000. Anfield Capital Management LLC raised its position in Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the period. Monetary Solutions Ltd acquired a new position in Medtronic during the fourth quarter worth $27,000. Board of the Pension Protection Fund acquired a new position in Medtronic during the fourth quarter worth $29,000. Finally, GoalVest Advisory LLC acquired a new position in Medtronic during the fourth quarter worth $29,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).